Thyrocare Technologies Reschedules Q4 FY26 Earnings Call to May 12, 2026

Thyrocare Technologies Limited has rescheduled its earnings conference call for analysts and investors, originally cancelled from May 07, 2026, to Tuesday, May 12, 2026, at 9:00 A.M. (IST). The revised schedule was communicated to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Rescheduled Q4 FY26 Conference Call

The conference call has been arranged by the company's management to discuss its audited financial results for the quarter and financial year ended March 31, 2026. The earlier call, which had been scheduled for May 07, 2026, at 5:30 P.M. (IST), was cancelled due to unforeseen circumstances. The company had previously referenced intimations to the exchanges dated April 29, 2026, and May 04, 2026, in connection with the original scheduling.

The key details of the rescheduled conference call are as follows:

Parameter:	Details
Revised Date:	Tuesday, May 12, 2026
Revised Time:	9:00 A.M. (IST)
Purpose:	Audited Financial Results for Q4 and FY ended March 31, 2026
Universal Access Numbers:	+91 22 6280 1408 / +91 22 7115 8296
Regulatory Reference:	Regulation 30, SEBI (LODR) Regulations, 2015

Senior Management Speakers

The call will feature participation from Thyrocare Technologies' senior management team. The following speakers are scheduled to address analysts and investors:

Speaker:	Designation
Mr. Rahul Guha	Chairman, MD & CEO
Mr. Rajdeep Panwar	CCO
Dr. Ramesh Kinha	COO
Mr. Vikram Gupta	CFO
Mr. Preet Joshi	Manager – Strategy & Investor Relations

Disclosure and Compliance

The disclosure was signed by Brijesh Kumar, Company Secretary and Compliance Officer of Thyrocare Technologies Limited, on May 07, 2026. Investors and analysts may also access the call via a webcast link provided in the enclosed invite. The company has confirmed that dial-in details are available in the copy of the enclosed invite shared with the exchanges.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.36%	+21.53%	+28.45%	+4.92%	+58.20%	+37.76%

Thyrocare Technologies Limited has issued a revised intimation to stock exchanges, updating the webcast link for its upcoming earnings conference call scheduled for May 7, 2026. The revision, filed on May 4, 2026, references the company's earlier intimation dated April 29, 2026, and confirms that all other details of the conference call remain unchanged.

Revised Conference Call Details

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has notified both the National Stock Exchange of India Limited and BSE Limited of the updated webcast link. The earnings conference call will be held on Thursday, May 7, 2026, at 5:30 PM IST, to discuss the company's audited financial results for the quarter and financial year ended March 31, 2026.

Conference Call Details:	Information
Date:	May 7, 2026
Day:	Thursday
Time:	5:30 PM IST
Reporting Period:	Q4 and FY ended March 31, 2026
Universal Access Numbers:	+91 22 6280 1408, +91 22 7115 8296
Confirmation Number:	6099720
Revised Webcast Link:	https://event.choruscall.com/mediaframe/webcast.html?webcastid=k7c1G75L
Event ID:	THY070526

Board Meeting Agenda

The board of directors meeting, also scheduled for May 7, 2026, will focus on two primary matters. Directors will consider and approve the audited standalone and consolidated financial results for both the quarter and financial year ended March 31, 2026. The board will also deliberate on recommending a final dividend for the financial year 2025-26, subject to board discretion.

Meeting Details:	Information
Date:	May 7, 2026
Day:	Thursday
Board Meeting Agenda:	Audited Financial Results Approval
Reporting Period:	Q4 and FY ended March 31, 2026
Dividend Consideration:	Final Dividend Recommendation

Senior Management Participation

The earnings call will feature comprehensive participation from Thyrocare's leadership team. The discussion will be led by Chairman, MD & CEO Mr. Rahul Guha, supported by Chief Commercial Officer Mr. Rajdeep Panwar and Chief Operating Officer Dr. Rameshinha. Financial insights will be provided by CFO Mr. Vikram Gupta, while Mr. Preet Joshi, Manager - Strategy & Investor Relations, will facilitate investor interactions.

Management Team:	Designation
Mr. Rahul Guha:	Chairman, MD & CEO
Mr. Rajdeep Panwar:	CCO
Dr. Rameshinha:	COO
Mr. Vikram Gupta:	CFO
Mr. Preet Joshi:	Manager - Strategy & Investor Relations

Trading Window Restrictions

In accordance with regulatory requirements, Thyrocare Technologies has implemented trading window restrictions to prevent insider trading. The trading window closed on April 1, 2026, affecting all designated persons and their immediate relatives from dealing in the company's equity shares. The window is set to reopen 48 hours after the results declaration.

Trading Window Status:	Details
Closure Date:	April 1, 2026
Applicable Regulations:	SEBI Insider Trading Regulations 2015
Affected Parties:	Designated Persons and Immediate Relatives
Reopening Timeline:	48 hours after results declaration

Regulatory Compliance

Both the original board meeting intimation and the revised conference call notification have been filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Brijesh Kumar signed the revised notification on May 4, 2026, ensuring proper regulatory disclosure to stock exchanges where the company's shares are listed. The updated information is also available on the company's website at https://investor.thyrocare.com/financials/quarterly-financial-results/ .